HC Wainwright Issues Pessimistic Outlook for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for shares of Harrow in a research note issued on Wednesday, August 12th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.26. The consensus estimate for Harrow’s current full-year earnings is $0.30 per share. HC Wainwright also issued estimates for Harrow’s FY2026 earnings at ($0.57) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.12) EPS and FY2027 earnings at $0.88 EPS.

Other equities research analysts have also issued reports about the stock. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Wall Street Zen cut Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Cantor Fitzgerald lowered their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Finally, BTIG Research reiterated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research report on Tuesday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $69.43.

Harrow Stock Down 1.2%

HROW stock opened at $38.87 on Friday. The stock has a market cap of $1.46 billion, a P/E ratio of -38.87 and a beta of 0.28. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30. Harrow has a twelve month low of $28.54 and a twelve month high of $54.85. The company’s 50 day moving average is $40.81 and its two-hundred day moving average is $39.88.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.28). The business had revenue of $70.66 million during the quarter, compared to analysts’ expectations of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 31.83%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. acquired a new position in Harrow in the 4th quarter worth approximately $26,000. KBC Group NV acquired a new position in Harrow in the 1st quarter worth about $31,000. Raymond James Financial Inc. bought a new stake in shares of Harrow in the 2nd quarter valued at approximately $48,000. SBI Securities Co. Ltd. increased its holdings in Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after buying an additional 846 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Harrow during the 2nd quarter worth about $72,000. Institutional investors own 72.76% of the company’s stock.

Insider Buying and Selling at Harrow

In other Harrow news, Director Adrienne L. Graves acquired 1,000 shares of Harrow stock in a transaction dated Monday, May 18th. The stock was acquired at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at approximately $31,070. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 12.80% of the stock is currently owned by company insiders.

Key Stories Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: HC Wainwright reaffirmed its longer-term outlook for Harrow by projecting $1.07 in fourth-quarter 2027 EPS, slightly above its previous $1.06 estimate. The firm also expects Harrow to reach $0.88 in full-year 2027 EPS, despite lowering that estimate from $1.14. HC Wainwright estimates
• Positive Sentiment: A Seeking Alpha analysis characterized Harrow’s second-quarter performance as a potential turnaround and rated the shares a cautious buy, suggesting that improving operations could support future growth. Harrow: The Q2 Turnaround Is Enough For A Cautious Buy
• Positive Sentiment: BTIG Research reaffirmed its Buy rating, while coverage highlighted Harrow’s new eye-care product launch and acquisition as potential sources of additional growth. BTIG Research Reaffirms Buy Rating
• Neutral Sentiment: Viatris’ planned sale of Tyrvaya could create an opportunity for Harrow to expand the product into a larger growth engine, though the investment case depends on execution and commercial adoption. Tyrvaya growth opportunity
• Negative Sentiment: HC Wainwright sharply reduced its forecasts: FY2026 EPS moved from $0.15 to a loss of $0.57, Q3 2026 EPS from $0.26 to $0.01, Q1 2027 EPS from a $0.43 loss to a $0.63 loss, and Q2 2027 EPS from a $0.03 loss to a $0.12 loss. Zacks Research also downgraded Harrow from “Hold” to “Strong Sell.” Zacks downgrade
• Negative Sentiment: The stock gapped down following quarterly results in which Harrow reported a $0.46 per-share loss, missing the $0.18 consensus estimate, although revenue of $70.66 million modestly exceeded expectations. Harrow shares gap down following weak earnings

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.